Indeed, cessation of the vismodegib treatment of Ptch/p53-mutant BCC not only leads to a loss of Hh-signaling marker gene expression but, also, to changes of HF stem cell-like to IFE- and isthmus-like expression profiles of the remaining BCC [21]. This evidence concerns the gene TP53 and hydrops fetalis.